New cell therapy TRX319 aims to slow progressive MS

NCT ID NCT07477639

Recruiting now Disease control Sponsor: Tr1X, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 19, 2026 · Last updated May 01, 2026 · Updated 6 times

Summary

This early-stage trial tests TRX319, a cell therapy, in 39 adults with primary or secondary progressive MS. The goal is to see if it is safe, find the best dose, and check if pre-treatment with another drug helps it work. Participants receive up to 3 doses over a year and undergo blood tests, MRI scans, and spinal taps to monitor safety and effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Kansas Medical Center
RECRUITING

Kansas City, Kansas, 66160, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Washington University, St. Louis
RECRUITING

St Louis, Missouri, 63110, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS MULTIPLE SCLEROSIS (MS) PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (MS) SECONDARY PROGRESSIVE PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)